EMA restricts use of Keytruda and Tecentriq in bladder cancer

View source ↗

Summary

The European Medicines Agency restricts the use of Keytruda (pembrolizumab) and Tecentriq (atezolizumab) for bladder cancer due to concerns requiring more preci…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Tecentriq (atezolizumab)